HC Wainwright & Co. Reiterates Buy on Kyverna Therapeutics, Maintains $25 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 89.1%

Neg 0% Neu 89.1% Pos 0%

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Kyverna Therapeutics (NASDAQ:KYTX) with a Buy and maintains $25 price target.